Last reviewed · How we verify
Tegafur, Gimeracil and Oteracil Potassium
Tegafur, Gimeracil and Oteracil Potassium, marketed by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, holds a position in the oncology market with its unique combination therapy. The key composition patent, set to expire in 2028, provides a significant period of exclusivity and competitive advantage. The primary risk lies in the potential for increased competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Tegafur, Gimeracil and Oteracil Potassium |
|---|---|
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (PHASE2)
- A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma (PHASE3)
- A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (PHASE1)
- Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ (PHASE2)
- Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ (PHASE2)
- QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer (PHASE2)
- A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10 (PHASE2)
- PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: